Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to show that substitution of the usual lipid emulsion
(Intralipid 20%®) at a dose between 0.5 and 1.0 g/kg/infusion of parenteral nutrition
(n-6:n-3 ratio = 7:1) by an equivalent dose of 0.5 to 1 g/kg/infusion of another lipid
emulsion, OMEGAVEN 10%® very rich in omega-3 (n-3) (n-6:n-3 ratio = 1:7) induces regression
of PNALD due to the anti-inflammatory and anti-fibrotic effects of n-3 EFA.
Regression of liver disease will be defined by normalization of the five liver function tests
(LFT): conjugated bilirubin, gamma GT, alkaline phosphatase, AST and ALT transaminases.